Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXA-G1.1-NN oral norovirus vaccine multi-dose study
NCT05213728Phase 1Completed
- Sponsor
- Vaxart, Inc.
- Start
- Jan 2022
- Primary completion
- Feb 2022
- Modality
- Drug Delivery Systems, Vaccines & Immunotherapeutics, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VXA-GI.1.NN in norovirus infection, sponsored by Vaxart, Inc. Primary endpoints: Rate of Solicited Symptoms of Reactogenicity at Day 8, VP1-specific Immunoglobin A (IgA) antibody-secreting cells (ASC) at Day 8 and 3 more. Started Jan 2022; status: completed.
02
Drugs
VXA-GI.1.NN
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT05213728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05213728.